Transcranial Pulse Stimulation for Alzheimer’s Patients

作者： Celine Cont1,2,3, Barbara S. Reinboth2, Carolin Schütz1,3, Nathalie Stute1, Anastasia Galli1,3, Christina Schulte1, Lars Wojtecki1,2,3 1Department of Neurology and Neurorehabilitation, Hospital Zum Heiligen Geist,Academic Teaching Hospital of the Heinrich-Heine-University Duesseldorf, 2Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty,Heinrich-Heine-University Düsseldorf, 3Neurologische Praxis am Neurozentrum Kempen, Prof. Dr. med. Lars Wojtecki

简介：

Overview

This article details the procedure of transcranial pulse stimulation (TPS) in Alzheimer's disease patients, outlining the indications, methodology, and future prospects. TPS is a non-invasive neuromodulation therapy that showed significant cognitive and emotional improvements in subjects across different stages of the disease.

Key Study Components

Area of Science

• Neuroscience
• Non-invasive therapies
• Alzheimer's disease interventions

Background

• Transcranial pulse stimulation (TPS) is explored for safety and effectiveness.
• Focus on real-world data collection across Alzheimer's disease stages.
• Emphasis on reaching patients with moderate to severe symptoms.
• Overall aim to assess sustained effects and treatment safety through registry establishment.

Purpose of Study

• To evaluate the safety and potential efficacy of TPS in Alzheimer's patients.
• To gather data on cognitive and emotional improvements post-treatment.
• To develop long-term analyses of TPS effects across different levels of disease progression.

Methods Used

• The study employed TPS as a therapeutic approach.
• Patients were monitored for responses and potential side effects.
• Careful calibration and specific target areas were determined using MRI data.
• Key logistical steps included setting treatment parameters and patient positioning.

Main Results

• TPS showed a reduction in ADAS total scores from 30.2 to 25.8 and in ADAS cog scores from 25.8 to 23.3.
• An overall improvement of 15.76% in ADAS total scores and 8.65% in ADAS cog scores indicated notable cognitive and emotional enhancements.
• These results highlight TPS as a beneficial adjunctive therapy for Alzheimer's patients.

Conclusions

• The study demonstrates the promise of TPS as a safe add-on therapy for Alzheimer’s treatment.
• It emphasizes the importance of tailoring the approach to individual patient needs across disease stages.
• The ongoing establishment of a registry aims to enhance understanding of TPS’s efficacy and safety in future applications.

Frequently Asked Questions